Top

Published in:

01-08-2018 | Neurology and Preclinical Neurological Studies - Review Article

The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective

Authors: Manolo Carta, Anders Björklund

Published in: Journal of Neural Transmission | Issue 8/2018

Abstract

During the last decade, the serotonergic system has emerged as a key player in the appearance of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Clinical investigations, based on imaging and postmortem analyses, suggest that the serotonin neurons are also involved in the etiology of this complication of long-term L-DOPA treatment in parkinsonian patients. These findings have stimulated efforts to develop new therapies using drugs targeting the malfunctioning serotonin neurons. In this review, we summarize the experimental and clinical data obtained so far and discuss the prospects for further development of this therapeutic strategy.

Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58(3):193–199CrossRefPubMed

Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667(2):295–299CrossRefPubMed

Arai R, Karasawa N, Geffard M, Nagatsu I (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195(3):195–198CrossRefPubMed

Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B (2010) Synaptic dysfunction in Parkinson’s disease. Biochem Soc Trans 38(2):493–497CrossRefPubMed

Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson’s disease. Mov Disord 20(8):932–936CrossRefPubMed

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 132:96–168CrossRefPubMed

Beaudoin-Gobert M, Epinat J, Metereau E, Duperrier S, Neumane S, Ballanger B, Lavenne F, Liger F, Tourvielle C, Bonnefoi F, Costes N, Bars DL, Broussolle E, Thobois S, Tremblay L, Sgambato-Faure V (2015) Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. Brain 138(Pt 9):2632–2647CrossRefPubMed

Bezard E, Carta M (2015) Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease? Brain 138(Pt 4):829–830CrossRefPubMed

Bezard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013a) Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neurosci Res 77(4):242–246CrossRefPubMed

Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013b) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28(8):1088–1096CrossRefPubMed

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87(7):1645–1658CrossRefPubMedPubMedCentral

Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL (2012) Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 36(6):2839–2848CrossRefPubMedPubMedCentral

Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198:245–251CrossRefPubMed

Carta M, Tronci E (2014) Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 5:78CrossRefPubMedPubMedCentral

Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain J Neurol 130(Pt 7):1819–1833CrossRef

Carta AR, Frau L, Pinna A, Morelli M (2010) Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol 224(2):395–402CrossRefPubMed

Cenci MA (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Amino Acids 23(1–3):105–109CrossRefPubMed

Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209–233CrossRefPubMedPubMedCentral

Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10(8):2694–2706CrossRefPubMed

Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell’isola R, Katzman AC, Bishop C (2014) Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77:1–8CrossRefPubMed

Conti MM, Meadows SM, Melikhov-Sosin M, Lindenbach D, Hallmark J, Werner DF, Bishop C (2016) Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats. Neuropharmacology 110(Pt A):125–134CrossRefPubMed

de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain J Neurol 127(Pt 12):2747–2754CrossRef

Dupre KB, Eskow KL, Barnum CJ, Bishop C (2008) Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55(8):1321–1328CrossRefPubMedPubMedCentral

Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229(2):288–299CrossRefPubMedPubMedCentral

Dupre KB, Ostock CY, George JA, Eskow Jaunarajs KL, Hueston CM, Bishop C (2013) Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem Neurosci 4(5):747–760CrossRefPubMedPubMedCentral

Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87(3):306–314CrossRefPubMed

Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63(7):610–620CrossRefPubMedPubMedCentral

Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M (2015) Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Neuroscience 298:389–396CrossRefPubMed

Fieblinger T, Cenci MA (2015) Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. Mov Disord 30(4):484–493CrossRefPubMed

Fieblinger T, Graves SM, Sebel LE, Alcacer C, Plotkin JL, Gertler TS, Chan CS, Heiman M, Greengard P, Cenci MA, Surmeier DJ (2014) Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun 5:5316CrossRefPubMedPubMedCentral

Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914–2922CrossRefPubMed

Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179–186CrossRefPubMed

Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinson Relat Disord 15(6):445–452CrossRef

Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 48(4):503–516CrossRefPubMed

Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, Sohn YH, Kim JS, Lee PH (2014) Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology 82(18):1597–1604CrossRefPubMed

Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P (2005) Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci 21(12):3240–3250CrossRefPubMed

Jaunarajs KL, Dupre KB, Steiniger A, Klioueva A, Moore A, Kelly C, Bishop C (2009) Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. NeuroReport 20(14):1265–1269CrossRefPubMed

Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M (2002) [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease]. No to shinkei = Brain Nerve 54(2):133–137PubMed

Kannari K, Shen H, Arai A, Tomiyama M, Baba M (2006) Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402(1–2):62–65CrossRefPubMed

Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS (2015) Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology 85(10):853–860CrossRefPubMed

Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C (2013) Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson’s disease. Brain Res 1537:327–339CrossRefPubMed

Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112(6):1465–1476CrossRefPubMed

Mazzucchi S, Frosini D, Ripoli A, Nicoletti V, Linsalata G, Bonuccelli U, Ceravolo R (2015) Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson’s disease. Acta Neurol Scand 131(3):191–195CrossRefPubMed

Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C (2017) Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of L-DOPA-induced dyskinesia. Exp Neurol 292:168–178CrossRefPubMed

Mignon LJ, Wolf WA (2005) 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson’s disease. NeuroReport 16(7):699–703CrossRefPubMed

Mosharov EV, Borgkvist A, Sulzer D (2015) Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord 30(1):45–53CrossRefPubMed

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Bjorklund A, Bezard E, Carta M (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131(Pt 12):3380–3394

Muñoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 219(1):298–307CrossRefPubMed

Navailles S, De Deurwaerdere P (2012) Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-DOPA-induced Dyskinesia. Parkinson’s Dis 2012:323686

Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson’s disease. Neurobiol Dis 38(1):136–143CrossRefPubMed

Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 41(2):585–590CrossRefPubMed

Navailles S, Lagiere M, Contini A, De Deurwaerdere P (2013) Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem Neurosci 4(5):680–692CrossRefPubMedPubMedCentral

Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27(2):58–62CrossRefPubMed

Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, Network NS-PC (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300–307CrossRefPubMed

Ostock CY, Dupre KB, Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, Bishop C (2011) Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 61(4):753–760CrossRefPubMedPubMedCentral

Pavon N, Martin AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiat 59(1):64–74CrossRefPubMed

Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6(5):501–506CrossRefPubMed

Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, Calabresi P (2005) Pathological synaptic plasticity in the striatum: implications for Parkinson’s disease. Neurotoxicology 26(5):779–783CrossRefPubMed

Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Investig 124(3):1340–1349CrossRefPubMed

Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG (2014) L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep 4:3730CrossRefPubMedPubMedCentral

Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson’s disease therapeutics. Mov Disord 26(6):1072–1082CrossRefPubMed

Roussakis AA, Politis M, Towey D, Piccini P (2016) Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology 86(12):1152–1158CrossRefPubMed

Rylander D, Parent M, O’Sullivan S, Dovero S, Lees A, Bezard E, Descarries L, Cenci MA (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68(5):619–628. https://doi.org/10.1002/ana.22097

Santini E, Valjent E, Fisone G (2008) Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275(7):1392–1399CrossRefPubMed

Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009) Inhibition of mTOR signaling in Parkinson’s disease prevents L-DOPA-induced dyskinesia. Sci Signal 2(80):ra36CrossRefPubMed

Smith R, Wu K, Hart T, Loane C, Brooks DJ, Bjorklund A, Odin P, Piccini P, Politis M (2015) The role of pallidal serotonergic function in Parkinson’s disease dyskinesias: a positron emission tomography study. Neurobiol Aging 36(4):1736–1742CrossRefPubMed

Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R, Shahani N, Tyagi R, Snyder SH, Usiello A (2011) Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci 15(2):191–193CrossRefPubMedPubMedCentral

Svenningsson P, Rosenblad C, af Edholm Arvidson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Bjorklund A, Widner H (2015) Eltoprazine counteracts L-dopa-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138(Pt 4):963–973. https://doi.org/10.1093/brain/awu409

Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10(3):631–634CrossRefPubMed

Tronci E, Napolitano F, Muñoz A, Fidalgo C, Rossi F, Bjorklund A, Usiello A, Carta M (2017) BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Exp Neurol 297:73–81CrossRefPubMed

Ulusoy A, Sahin G, Kirik D (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci USA 107(29):13159–13164CrossRefPubMed

Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiat 62(7):800–810CrossRefPubMed

Zhang X, Andren PE, Greengard P, Svenningsson P (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 105(6):2163–2168CrossRefPubMed

Title: The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
Authors: Manolo Carta
Anders Björklund
Publication date: 01-08-2018
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 8/2018
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-018-1865-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2018

Impulse control disorders in Parkinson’s disease

Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question

Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function

Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease

Levodopa-induced dyskinesia: clinical features, incidence, and risk factors

The striatal cholinergic system in l-dopa-induced dyskinesias